InvestWiserOncozenge AB
ONCOZ · Nasdaq Stockholm · Healthcare
3.52SEK
+1.9%last day
Price as of 2 October 2026
Performance
1 month
−8.0%
1 year
−41.3%
3 years, per year
+5.5%
5 years, per year
−20.8%
Largest fall, 3 years
−83.7%
Below the peak now
−76.2%
Volatility, 1 year
70.7%
Return with dividends reinvested.
Key figures
P/E
negative earnings
P/B
−19.2
Dividend yield
0.0%
Return on equity
−493.7%
Net margin
–
Market value
5 m USD
Quality, value and trend
Where Oncozenge stands against every Nordic stock today. 100 is best.
15
Profitability and a sound balance sheet over time. Better than 15% of Nordic stocks.
1
The price measured against earnings, assets and cash flow. Better than 1% of Nordic stocks.
5
The price development over the past year. Better than 5% of Nordic stocks.
1
Quality, value and trend together. Better than 1% of Nordic stocks.
About Oncozenge
Oncozenge AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 1 employees.
OncoZenge AB (publ), is a clinical-stage pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. The company offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was founded in 2020 and is headquartered in Bromma, Sweden.
See the full analysis in InvestWiser.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
See the full analysis